Press Releases
11/14/22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
11/10/22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
10/10/22
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
9/6/22
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
8/22/22
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022
8/10/22
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
7/18/22
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
7/13/22
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
7/13/22
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
7/12/22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
Displaying 1 - 10 of 17